Calciphylaxis Market Expected to Reach $11.68 Billion by 2034 with 11.59% CAGR, Driven by Rising CKD and ESRD Cases and Advances in Diagnostics and Therapies.

The calciphylaxis market is projected to reach USD 11.68 Billion by 2034, with a CAGR of 11.59%. The increasing incidence of chronic kidney disease (CKD) and end-stage renal disease (ESRD) drives demand. Advances in diagnostics and therapies, such as high-quality imaging and sodium thiosulfate, enhance growth. Key players include Amgen and Smith & Nephew.

The calciphylaxis market is poised for significant growth, with projections indicating a market value of USD 11.68 Billion by 2034, representing a Compound Annual Growth Rate (CAGR) of 11.59% over the period 2025-2034 [1].

Driving this growth is the increasing incidence of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Approximately 37 million Americans, or more than 1 in 7 U.S. adults, are impacted by CKD, and around 550,000 individuals are undergoing dialysis, leading to an average of nearly 2,000 cases of calciphylaxis annually [1]. The rising prevalence of diabetes and hypertension further exacerbates the risk of developing calciphylaxis, thereby increasing the demand for effective treatment and diagnostic methods.

Advancements in diagnostic techniques are significantly enhancing the capacity to address the growing needs in calciphylaxis management. High-quality ultrasound, CT angiography, and PET scans now provide accurate imaging of calcific deposits in blood vessels, facilitating early detection and treatment preparation [1]. The integration of AI algorithms with these imaging methods further improves diagnostic precision, while biomarkers derived from proteomic and genomic studies offer additional diagnostic options [1].

The market is segmented by treatment type, including drug therapy, hyperbaric oxygen therapy, and surgery, with key players focusing on developing novel drugs and wound care items to improve patient outcomes [1]. The market is also segmented by type, with non-uremic and uremic calciphylaxis, and by end users, including hospitals and clinics, homecare, and others [1].

Key players in the calciphylaxis market include Amgen Inc. and Smith & Nephew plc, among others. These companies are working on developing targeted therapies, such as sodium thiosulfate, to manage symptoms and enhance patients' quality of life [1]. Additionally, ProKidney Corp. (NASDAQ:PROK), a late-stage biotechnology company, is focused on developing a cell therapy called rilparencel to treat chronic kidney disease (CKD) [2].

The market is influenced by various trends, including increasing awareness about the condition, epidemiological studies, and therapeutic advances. The market is expected to be dominated by the United States and the EU-4 region, with Japan and India also showing significant growth potential [1].

References:
[1] https://www.globenewswire.com/news-release/2025/07/23/3120014/0/en/Calciphylaxis-Market-Forecast-Report-2025-2034-Rising-Incidence-of-Chronic-Kidney-Disease-CKD-and-End-Stage-Renal-Disease-ESRD-Fueling-Demand-and-Growth.html
[2] https://finance.yahoo.com/news/prokidney-corp-prok-completes-domestication-150325472.html